Integrated single-use freeze-thaw assemblies with reliable component parts, such as the connectors supplied by CPC, have become the primary implementation choice for achieving successful drug substance transfers between manufacturing facilities.
The AseptiQuik G 1-1/2” Sanitary option expands CPC’s extensive termination offerings, which now include six termination sizes from 1/8” to 1” hose barbs, with 3/4” and 1-1/2” sanitary options.
CPC has an army of biopharma experts ready to provide you with highly-tested bio-pharma connectors and global support.
The traditional method of big batch manufacturing must change as biopharmaceutical companies move away from the one-size-fits-all blockbuster pharmaceutical model toward increasingly more innovative, targeted biologics that deliver better patient outcomes.
Tube welding versus using aseptic connectors—as with any debate, there are strong opinions on both sides. Following are some factors to consider that may tip the scale in favor of aseptic connectors.
Three considerations to give you confidence when selecting fluid handling connectors for your bio application.
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has published technology roadmaps addressing needs and gaps in three key product areas: gene therapy, antibody-dug conjugates, and vaccines. The roadmaps were developed with the collaborative input of industry, academic, and government experts. This article highlights technology opportunities for gene therapy manufacturing.
Are you up to the task of bringing a biologic to market? Do you have a strategy and plan in place? Explore some of the questions to consider in order to map out a successful pathway and avoid pitfalls.
Building a bioprocessing facility is usually a complicated process and requires partnering with not only drug developers, but also many different experts in various industries. BeiGene, a commercial-stage biotechnology company, can attest to these challenges.
Overcoming the challenges of manufacturing and administering a complex product to any patient is critical for delivering cell therapies. Two industry experts detail strategies to meet supply chain challenges.